Hrishikesh K. Srinagesh, Vishal Gupta, Amy Zhang, Michael R Grunwald, Matthew P Connor, Vamsi Kota, Jacob Boccucci, M. Ulrickson, Roshini Pradeep, L Hill, Stephanie B. Tsai, TIMOTHY E. O'CONNOR, Karamjeet Sandhu, Anjali S. Advani, Ran Reshef, Christian Gordillo, Marlise R. Luskin, Evan C. Chen, Chenyu Lin, Ryan D. Cassaday, Noam E. Kopmar, Navneet S. Majhail, Minoo Battiwalla, Stephen A. Strickland, C F Lee, Silvina Odstrcil Bobillo, Talal Hilal, Jae H Park, Yannis K. Valtis, Rawan Faramand, Melhem M Solh, Caitlin Guzowski, Sumithira Vasu, Jessica Leonard, Virginia Tan, Eunice S. Wang, Ross McCauley, Joshua Sasine, Kevin Tang, Miller Kk, Katherine C. Sutherland, Michael Daunov, Razan Mohty, Omer Jamy, Muthu Sendhil Kumaran, Rasmus T. Hoeg, Kaitlyn C. Dykes, Aaron Logan, Tamer Othman, Wendy A Stock, Marc S. Schwartz, Kenneth Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan O. Oluwole, Bhagirathbhai Dholaria, Kristen M O'Dwyer, Jozal Moore, Gregory W. Roloff, Noelle V. Frey, Ibrahim Aldoss, B. D. Shah, Caspian Oliai, Lori Muffly
ABSTRACT: In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.